世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

幹細胞治療市場


Stem Cell Therapies Market

幹細胞は未分化な生物学的細胞であり、あらゆる種類の細胞に分裂する可能性を持っている。幹細胞が分裂すると、それぞれの新しい細胞は新しい幹細胞になるか、あるいは筋肉細胞、赤血球、脳細胞など、特定の機能... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Future Market Insights
フューチャーマーケットインサイツ
2022年6月28日 US$5,000
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
250 英語

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

幹細胞は未分化な生物学的細胞であり、あらゆる種類の細胞に分裂する可能性を持っている。幹細胞が分裂すると、それぞれの新しい細胞は新しい幹細胞になるか、あるいは筋肉細胞、赤血球、脳細胞など、特定の機能を持つ別の細胞のようになる。

幹細胞には2種類ある。

胚性細胞
成体幹細胞
出生直後の臍帯血から採取される幹細胞。この細胞は特定の条件下で保存することができる。幹細胞は骨髄や脂肪組織からも採取できる。

胚細胞は発生段階で外胚葉、内胚葉、中胚葉に分化することができる。幹細胞は、生体や細胞、組織の再生のための治療や手術に使用される。

幹細胞は、胃腸疾患、代謝性疾患、免疫系疾患、中枢神経系疾患、心血管系疾患、創傷および損傷、眼疾患、筋骨格系疾患の治療に使用される。

成体細胞の採取は胚細胞に比べてやや難しい。なぜなら、成体細胞は自分の体内に存在し、採取がやや困難だからである。

幹細胞治療市場:促進要因と抑制要因

医療における技術の進歩は、今や生命を脅かす病気を治療し、有望な結果をもたらしている。幹細胞治療には、他の細胞や身体の器官を再生させるなど、非常に多くの利点がある。これがこの市場の主な促進要因である。これらの治療法は、多くの生命を脅かす治療に役立っている。疾患の有病率の増加が幹細胞治療市場を牽引しており、医療における技術の進歩も市場を牽引している。医療における技術の進歩は、今や人々を生命を脅かす合併症から救っている。

また、政府や民間団体からの資金提供の増加や、幹細胞療法に注力する企業の増加も市場を牽引している。

しかし、胚性幹細胞を採取するのは簡単だが、成体幹細胞や体性幹細胞を採取するのは難しく、採取した幹細胞を保存するためにはより多くの注意を払わなければならない。

幹細胞治療市場セグメンテーション

幹細胞治療は以下のタイプに分類される。

治療法に基づく

同種幹細胞治療
自家幹細胞治療
用途別

胃腸疾患
代謝疾患
免疫系疾患
中枢神経系疾患
循環器系疾患
傷と怪我
眼疾患
筋骨格系疾患
エンドユーザー別

病院
外来手術センター
幹細胞治療市場概要

医療における急速な技術的優位性とその有望な成果により、幹細胞治療の利用は増加し、予測期間(2015-2025年)には2桁成長が見込まれる。

幹細胞治療市場地域別展望

地理的地域によって、世界の幹細胞治療市場は7つの主要地域に区分される:北米、南米、東欧、西欧、日本を除くアジア太平洋地域、日本、中東・アフリカ。

北米は先進国であり、医療技術も発達しており、人々の医療に対する意識も高い。アジア太平洋地域では、中国とインドがヘルスケアセットアップで急成長している。ヨーロッパもこの市場で良好な成長を見せている。

幹細胞治療市場主要プレイヤー

この市場における主なプレーヤーは以下の通りである。

メソブラスト社
ロズリン・セルズ
Regeneus Ltd、
ReNeuron Group plc、
インターナショナル・ステム・セル・コーポレーション
この調査レポートは、市場の包括的な評価を提示し、思慮深い洞察、事実、過去のデータ、統計的に裏付けられた、業界で検証された市場データを含んでいます。また、適切な仮定と方法論を用いた予測も含まれています。この調査レポートは、市場セグメント、地域、タイプ、技術、用途などのカテゴリー別に分析と情報を提供しています。

本レポートでは、以下の項目について網羅的に分析しています:

市場セグメント
市場ダイナミクス
市場規模
需要と供給
現在のトレンド/問題/課題
競合・参入企業
テクノロジー
バリューチェーン
地域分析

北米(米国、カナダ)
中南米(メキシコ、ブラジル)
西欧(ドイツ、イタリア、フランス、イギリス、スペイン、北欧諸国、ベルギー、オランダ、ルクセンブルク)
東欧(ポーランド、ロシア)
アジア太平洋(中国、インド、ASEAN、オーストラリア、ニュージーランド)
日本
中東・アフリカ(GCC、南アフリカ、北アフリカ)
本レポートは、業界アナリストによる生の情報、質的・量的評価、業界専門家およびバリューチェーン全体にわたる業界参加者からのインプットをまとめたものです。本レポートでは、親市場の動向、マクロ経済指標、支配要因について、セグメントごとの市場魅力とともに詳細に分析しています。また、様々な市場要因が市場セグメントや地域に与える定性的な影響もマッピングしています。

レポートのハイライト

親市場の詳細な概要
業界における市場ダイナミクスの変化
詳細な市場セグメンテーション
過去、現在、そして予測される市場規模(数量ベース、金額ベース
最近の業界動向と発展
競合他社の状況
主要企業の戦略と提供製品
潜在的かつニッチなセグメント、有望な成長を示す地理的地域
市場パフォーマンスに関する中立的な視点
市場関係者が市場での足跡を維持・強化するための必携情報
注 - レポートに記載されている事実、意見、分析はすべて各アナリストのものです。これらは必ずしもFuture Market Insightsの正式な立場や見解を反映するものではありません。

ページTOPに戻る


目次

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2017-2021 and Forecast, 2022-2032

    4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021

    4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Therapy Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) Analysis By Therapy Type, 2017-2021

    5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Therapy Type, 2022-2032

        5.3.1. Allogeneic Therapy

        5.3.2. Autologous Therapy

    5.4. Y-o-Y Growth Trend Analysis By Therapy Type, 2017-2021

    5.5. Absolute $ Opportunity Analysis By Therapy Type, 2022-2032

Deep-dive segmentation will be available in the sample on request

6. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Indication

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Mn) Analysis By Indication, 2017-2021

    6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Indication, 2022-2032

        6.3.1. Autoimmune Diseases

        6.3.2. Musculoskeletal Disorders

        6.3.3. Acute Graft Host Disease

        6.3.4. Trauma Injuries

        6.3.5. Others

    6.4. Y-o-Y Growth Trend Analysis By Indication, 2017-2021

    6.5. Absolute $ Opportunity Analysis By Indication, 2022-2032

Deep-dive segmentation will be available in the sample on request

7. Global Market Analysis 2017-2021 and Forecast 2022-2032, By End User

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Mn) Analysis By End User, 2017-2021

    7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End User, 2022-2032

        7.3.1. Hospitals

        7.3.2. Acute Care Facilities

        7.3.3. Specialized Clinics

    7.4. Y-o-Y Growth Trend Analysis By End User, 2017-2021

    7.5. Absolute $ Opportunity Analysis By End User, 2022-2032

Deep-dive segmentation will be available in the sample on request

8. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Stem Cell Type

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ Mn) Analysis By Stem Cell Type, 2017-2021

    8.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Stem Cell Type, 2022-2032

        8.3.1. Embryonic Stem Cells

        8.3.2. Tissue-specific Stem Cells

        8.3.3. Mesenchymal Stem Cells

        8.3.4. Induced Pluripotent Stem Cells

    8.4. Y-o-Y Growth Trend Analysis By Stem Cell Type, 2017-2021

    8.5. Absolute $ Opportunity Analysis By Stem Cell Type, 2022-2032

Deep-dive segmentation will be available in the sample on request

9. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Region

    9.1. Introduction

    9.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021

    9.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032

        9.3.1. North America

        9.3.2. Latin America

        9.3.3. Europe

        9.3.4. East Asia

        9.3.5. South Asia & Pacific

        9.3.6. MEA

    9.4. Market Attractiveness Analysis By Region

10. North America Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        10.2.1. By Country

            10.2.1.1. U.K.

            10.2.1.2. Canada

        10.2.2. By Therapy Type

        10.2.3. By Indication

        10.2.4. By End User

        10.2.5. By Stem Cell Type

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Therapy Type

        10.3.3. By Indication

        10.3.4. By End User

        10.3.5. By Stem Cell Type

    10.4. Key Takeaways

11. Latin America Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        11.2.1. By Country

            11.2.1.1. Brazil

            11.2.1.2. Mexico

            11.2.1.3. Rest of Latin America

        11.2.2. By Therapy Type

        11.2.3. By Indication

        11.2.4. By End User

        11.2.5. By Stem Cell Type

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Therapy Type

        11.3.3. By Indication

        11.3.4. By End User

        11.3.5. By Stem Cell Type

    11.4. Key Takeaways

12. Europe Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        12.2.1. By Country

            12.2.1.1. Germany

            12.2.1.2. U.K.

            12.2.1.3. France

            12.2.1.4. Spain

            12.2.1.5. Italy

            12.2.1.6. Rest of Europe

        12.2.2. By Therapy Type

        12.2.3. By Indication

        12.2.4. By End User

        12.2.5. By Stem Cell Type

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Therapy Type

        12.3.3. By Indication

        12.3.4. By End User

        12.3.5. By Stem Cell Type

    12.4. Key Takeaways

13. East Asia Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Therapy Type

        13.2.3. By Indication

        13.2.4. By End User

        13.2.5. By Stem Cell Type

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Therapy Type

        13.3.3. By Indication

        13.3.4. By End User

        13.3.5. By Stem Cell Type

    13.4. Key Takeaways

14. South Asia & Pacific Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        14.2.1. By Country

            14.2.1.1. India

            14.2.1.2. Thailand

            14.2.1.3. Indonesia

            14.2.1.4. Malaysia

            14.2.1.5. Singapore

            14.2.1.6. Australia

            14.2.1.7. New Zealand

            14.2.1.8. Rest of South Asia & Pacific

        14.2.2. By Therapy Type

        14.2.3. By Indication

        14.2.4. By End User

        14.2.5. By Stem Cell Type

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Therapy Type

        14.3.3. By Indication

        14.3.4. By End User

        14.3.5. By Stem Cell Type

    14.4. Key Takeaways

15. MEA Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    15.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    15.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Therapy Type

        15.2.3. By Indication

        15.2.4. By End User

        15.2.5. By Stem Cell Type

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Therapy Type

        15.3.3. By Indication

        15.3.4. By End User

        15.3.5. By Stem Cell Type

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. U.K.

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2021

            16.1.2.1. By Therapy Type

            16.1.2.2. By Indication

            16.1.2.3. By End User

            16.1.2.4. By Stem Cell Type

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2021

            16.2.2.1. By Therapy Type

            16.2.2.2. By Indication

            16.2.2.3. By End User

            16.2.2.4. By Stem Cell Type

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2021

            16.3.2.1. By Therapy Type

            16.3.2.2. By Indication

            16.3.2.3. By End User

            16.3.2.4. By Stem Cell Type

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2021

            16.4.2.1. By Therapy Type

            16.4.2.2. By Indication

            16.4.2.3. By End User

            16.4.2.4. By Stem Cell Type

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2021

            16.5.2.1. By Therapy Type

            16.5.2.2. By Indication

            16.5.2.3. By End User

            16.5.2.4. By Stem Cell Type

    16.6. U.K.

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2021

            16.6.2.1. By Therapy Type

            16.6.2.2. By Indication

            16.6.2.3. By End User

            16.6.2.4. By Stem Cell Type

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2021

            16.7.2.1. By Therapy Type

            16.7.2.2. By Indication

            16.7.2.3. By End User

            16.7.2.4. By Stem Cell Type

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2021

            16.8.2.1. By Therapy Type

            16.8.2.2. By Indication

            16.8.2.3. By End User

            16.8.2.4. By Stem Cell Type

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2021

            16.9.2.1. By Therapy Type

            16.9.2.2. By Indication

            16.9.2.3. By End User

            16.9.2.4. By Stem Cell Type

    16.10. China

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2021

            16.10.2.1. By Therapy Type

            16.10.2.2. By Indication

            16.10.2.3. By End User

            16.10.2.4. By Stem Cell Type

    16.11. Japan

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2021

            16.11.2.1. By Therapy Type

            16.11.2.2. By Indication

            16.11.2.3. By End User

            16.11.2.4. By Stem Cell Type

    16.12. South Korea

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2021

            16.12.2.1. By Therapy Type

            16.12.2.2. By Indication

            16.12.2.3. By End User

            16.12.2.4. By Stem Cell Type

    16.13. India

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2021

            16.13.2.1. By Therapy Type

            16.13.2.2. By Indication

            16.13.2.3. By End User

            16.13.2.4. By Stem Cell Type

    16.14. Thailand

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2021

            16.14.2.1. By Therapy Type

            16.14.2.2. By Indication

            16.14.2.3. By End User

            16.14.2.4. By Stem Cell Type

    16.15. Indonesia

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2021

            16.15.2.1. By Therapy Type

            16.15.2.2. By Indication

            16.15.2.3. By End User

            16.15.2.4. By Stem Cell Type

    16.16. Malaysia

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2021

            16.16.2.1. By Therapy Type

            16.16.2.2. By Indication

            16.16.2.3. By End User

            16.16.2.4. By Stem Cell Type

    16.17. Singapore

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2021

            16.17.2.1. By Therapy Type

            16.17.2.2. By Indication

            16.17.2.3. By End User

            16.17.2.4. By Stem Cell Type

    16.18. Australia

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2021

            16.18.2.1. By Therapy Type

            16.18.2.2. By Indication

            16.18.2.3. By End User

            16.18.2.4. By Stem Cell Type

    16.19. New Zealand

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2021

            16.19.2.1. By Therapy Type

            16.19.2.2. By Indication

            16.19.2.3. By End User

            16.19.2.4. By Stem Cell Type

    16.20. GCC Countries

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2021

            16.20.2.1. By Therapy Type

            16.20.2.2. By Indication

            16.20.2.3. By End User

            16.20.2.4. By Stem Cell Type

    16.21. South Africa

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2021

            16.21.2.1. By Therapy Type

            16.21.2.2. By Indication

            16.21.2.3. By End User

            16.21.2.4. By Stem Cell Type

    16.22. Israel

        16.22.1. Pricing Analysis

        16.22.2. Market Share Analysis, 2021

            16.22.2.1. By Therapy Type

            16.22.2.2. By Indication

            16.22.2.3. By End User

            16.22.2.4. By Stem Cell Type

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Therapy Type

        17.3.3. By Indication

        17.3.4. By End User

        17.3.5. By Stem Cell Type

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. Vericel Corporation

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. Cyagen Biosciences, Inc.

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. Stemcell Technologies Inc.

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. Celegene Corporation

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. Cellular Dynamics International

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. Cytori Therapeutics, Inc.

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. Fibrocell Science, Inc.

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. Mesoblast Ltd

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. Regeneus Ltd

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. EMD Millipore Corporation

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

        18.1.11. ReNeuron Group plc

            18.1.11.1. Overview

            18.1.11.2. Product Portfolio

            18.1.11.3. Profitability by Market Segments

            18.1.11.4. Sales Footprint

            18.1.11.5. Strategy Overview

                18.1.11.5.1. Marketing Strategy

        18.1.12. International Stem Cell Corporation

            18.1.12.1. Overview

            18.1.12.2. Product Portfolio

            18.1.12.3. Profitability by Market Segments

            18.1.12.4. Sales Footprint

            18.1.12.5. Strategy Overview

                18.1.12.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

 

ページTOPに戻る


 

Summary

Stem cells are undifferentiated biological cells, and having remarkable potential to divide into any kind of other cells. When a stem cell divides, each new cell will be a new stem cell or it will be like another cell which is having specific function such as a muscle cell, a red blood cell, brain cell and some other cells.

There are two types of stem cells

Embryonic cells
Adult stem or Somatic cells
Stem cells harvested from umbilical cord blood just after birth. And this cells can be stored in specific conditions. Stem cells also can be harvest from bone marrow, adipose tissue.

Embryonic cells can differentiate into ectoderm, endoderm and mesoderm in developing stage. Stem cells used in the therapies and surgeries for regeneration of organisms or cells, tissues.

Stem cells are used for the treatment of Gastro intestine diseases, Metabolic diseases, Immune system diseases, Central Nervous System diseases, Cardiovascular diseases, Wounds and injuries, Eye diseases, Musculoskeletal disorders.

Harvesting of Adult cell is somewhat difficult compare to embryonic cells. Because Adult cells available in the own body and it is somewhat difficult to harvest.

Stem Cell Therapies Market: Drivers and Restraints

Technology advancements in healthcare now curing life threatening diseases and giving promising results. Stem Cell Therapies having so many advantages like regenerating the other cells and body organisms. This is the main driver for this market. These therapies are useful in many life threatening treatments. Increasing the prevalence rate of diseases are driven the Stem Cell Therapies market, it is also driven by increasing technology advancements in healthcare. Technological advancements in healthcare now saving the population from life threatening complications.

Increasing funding from government, private organizations and increasing the Companies focus on Stem cell therapies are also driven this market

However, Collecting the Embryonic Stem cells are easy but Collecting Adult Stem cell or Somatic Stem cells are difficult and also we have to take more precautions for storing the collected stem cells.

Stem Cell Therapies Market: Segmentation

Stem Cell Therapies are segmented into following types

Based on treatment:

Allogeneic stem cell therapy
Autologous stem cell therapy
Based on application:

Gastro intestine diseases
Metabolic diseases
Immune system diseases
Central Nervous System diseases
Cardiovascular diseases
Wounds and injuries
Eye diseases
Musculoskeletal disorders
Based on End User:

Hospitals
Ambulatory Surgical centers
Stem Cell Therapies Market: Overview

With rapid technological advantage in healthcare and its promising results, the use of Stem Cell Therapies will increase and the market is expected to have a double digit growth in the forecast period (2015-2025).

Stem Cell Therapies Market: Region- wise Outlook

Depending on geographic regions, the global Stem Cell Therapies market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific excluding Japan, Japan and Middle East & Africa.

The use of Stem Cell Therapies is high in North America because it is highly developed region, having good technological advancements in healthcare setup and people are having good awareness about health care. In Asia pacific region china and India also having rapid growth in health care set up. Europe also having good growth in this market.

Stem Cell Therapies Market: Key Players

Some of the key players in this market are

Mesoblast Ltd.,
Roslin Cells,
Regeneus Ltd,
ReNeuron Group plc,
International Stem Cell Corporation.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

The report covers exhaustive analysis on:

Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Technology
Value Chain
Regional analysis includes

North America (U.S., Canada)
Latin America (Mexico. Brazil)
Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)
Eastern Europe (Poland, Russia)
Asia Pacific (China, India, ASEAN, Australia & New Zealand)
Japan
Middle East and Africa (GCC, S. Africa, N. Africa)
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

Detailed overview of parent market
Changing market dynamics in the industry
In-depth market segmentation
Historical, current and projected market size in terms of volume and value
Recent industry trends and developments
Competitive landscape
Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth
A neutral perspective on market performance
Must-have information for market players to sustain and enhance their market footprint.
NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.



ページTOPに戻る


Table of Contents

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2017-2021 and Forecast, 2022-2032

    4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021

    4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Therapy Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) Analysis By Therapy Type, 2017-2021

    5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Therapy Type, 2022-2032

        5.3.1. Allogeneic Therapy

        5.3.2. Autologous Therapy

    5.4. Y-o-Y Growth Trend Analysis By Therapy Type, 2017-2021

    5.5. Absolute $ Opportunity Analysis By Therapy Type, 2022-2032

Deep-dive segmentation will be available in the sample on request

6. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Indication

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Mn) Analysis By Indication, 2017-2021

    6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Indication, 2022-2032

        6.3.1. Autoimmune Diseases

        6.3.2. Musculoskeletal Disorders

        6.3.3. Acute Graft Host Disease

        6.3.4. Trauma Injuries

        6.3.5. Others

    6.4. Y-o-Y Growth Trend Analysis By Indication, 2017-2021

    6.5. Absolute $ Opportunity Analysis By Indication, 2022-2032

Deep-dive segmentation will be available in the sample on request

7. Global Market Analysis 2017-2021 and Forecast 2022-2032, By End User

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Mn) Analysis By End User, 2017-2021

    7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End User, 2022-2032

        7.3.1. Hospitals

        7.3.2. Acute Care Facilities

        7.3.3. Specialized Clinics

    7.4. Y-o-Y Growth Trend Analysis By End User, 2017-2021

    7.5. Absolute $ Opportunity Analysis By End User, 2022-2032

Deep-dive segmentation will be available in the sample on request

8. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Stem Cell Type

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ Mn) Analysis By Stem Cell Type, 2017-2021

    8.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Stem Cell Type, 2022-2032

        8.3.1. Embryonic Stem Cells

        8.3.2. Tissue-specific Stem Cells

        8.3.3. Mesenchymal Stem Cells

        8.3.4. Induced Pluripotent Stem Cells

    8.4. Y-o-Y Growth Trend Analysis By Stem Cell Type, 2017-2021

    8.5. Absolute $ Opportunity Analysis By Stem Cell Type, 2022-2032

Deep-dive segmentation will be available in the sample on request

9. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Region

    9.1. Introduction

    9.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021

    9.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032

        9.3.1. North America

        9.3.2. Latin America

        9.3.3. Europe

        9.3.4. East Asia

        9.3.5. South Asia & Pacific

        9.3.6. MEA

    9.4. Market Attractiveness Analysis By Region

10. North America Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        10.2.1. By Country

            10.2.1.1. U.K.

            10.2.1.2. Canada

        10.2.2. By Therapy Type

        10.2.3. By Indication

        10.2.4. By End User

        10.2.5. By Stem Cell Type

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Therapy Type

        10.3.3. By Indication

        10.3.4. By End User

        10.3.5. By Stem Cell Type

    10.4. Key Takeaways

11. Latin America Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        11.2.1. By Country

            11.2.1.1. Brazil

            11.2.1.2. Mexico

            11.2.1.3. Rest of Latin America

        11.2.2. By Therapy Type

        11.2.3. By Indication

        11.2.4. By End User

        11.2.5. By Stem Cell Type

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Therapy Type

        11.3.3. By Indication

        11.3.4. By End User

        11.3.5. By Stem Cell Type

    11.4. Key Takeaways

12. Europe Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        12.2.1. By Country

            12.2.1.1. Germany

            12.2.1.2. U.K.

            12.2.1.3. France

            12.2.1.4. Spain

            12.2.1.5. Italy

            12.2.1.6. Rest of Europe

        12.2.2. By Therapy Type

        12.2.3. By Indication

        12.2.4. By End User

        12.2.5. By Stem Cell Type

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Therapy Type

        12.3.3. By Indication

        12.3.4. By End User

        12.3.5. By Stem Cell Type

    12.4. Key Takeaways

13. East Asia Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Therapy Type

        13.2.3. By Indication

        13.2.4. By End User

        13.2.5. By Stem Cell Type

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Therapy Type

        13.3.3. By Indication

        13.3.4. By End User

        13.3.5. By Stem Cell Type

    13.4. Key Takeaways

14. South Asia & Pacific Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        14.2.1. By Country

            14.2.1.1. India

            14.2.1.2. Thailand

            14.2.1.3. Indonesia

            14.2.1.4. Malaysia

            14.2.1.5. Singapore

            14.2.1.6. Australia

            14.2.1.7. New Zealand

            14.2.1.8. Rest of South Asia & Pacific

        14.2.2. By Therapy Type

        14.2.3. By Indication

        14.2.4. By End User

        14.2.5. By Stem Cell Type

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Therapy Type

        14.3.3. By Indication

        14.3.4. By End User

        14.3.5. By Stem Cell Type

    14.4. Key Takeaways

15. MEA Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    15.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    15.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Therapy Type

        15.2.3. By Indication

        15.2.4. By End User

        15.2.5. By Stem Cell Type

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Therapy Type

        15.3.3. By Indication

        15.3.4. By End User

        15.3.5. By Stem Cell Type

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. U.K.

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2021

            16.1.2.1. By Therapy Type

            16.1.2.2. By Indication

            16.1.2.3. By End User

            16.1.2.4. By Stem Cell Type

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2021

            16.2.2.1. By Therapy Type

            16.2.2.2. By Indication

            16.2.2.3. By End User

            16.2.2.4. By Stem Cell Type

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2021

            16.3.2.1. By Therapy Type

            16.3.2.2. By Indication

            16.3.2.3. By End User

            16.3.2.4. By Stem Cell Type

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2021

            16.4.2.1. By Therapy Type

            16.4.2.2. By Indication

            16.4.2.3. By End User

            16.4.2.4. By Stem Cell Type

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2021

            16.5.2.1. By Therapy Type

            16.5.2.2. By Indication

            16.5.2.3. By End User

            16.5.2.4. By Stem Cell Type

    16.6. U.K.

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2021

            16.6.2.1. By Therapy Type

            16.6.2.2. By Indication

            16.6.2.3. By End User

            16.6.2.4. By Stem Cell Type

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2021

            16.7.2.1. By Therapy Type

            16.7.2.2. By Indication

            16.7.2.3. By End User

            16.7.2.4. By Stem Cell Type

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2021

            16.8.2.1. By Therapy Type

            16.8.2.2. By Indication

            16.8.2.3. By End User

            16.8.2.4. By Stem Cell Type

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2021

            16.9.2.1. By Therapy Type

            16.9.2.2. By Indication

            16.9.2.3. By End User

            16.9.2.4. By Stem Cell Type

    16.10. China

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2021

            16.10.2.1. By Therapy Type

            16.10.2.2. By Indication

            16.10.2.3. By End User

            16.10.2.4. By Stem Cell Type

    16.11. Japan

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2021

            16.11.2.1. By Therapy Type

            16.11.2.2. By Indication

            16.11.2.3. By End User

            16.11.2.4. By Stem Cell Type

    16.12. South Korea

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2021

            16.12.2.1. By Therapy Type

            16.12.2.2. By Indication

            16.12.2.3. By End User

            16.12.2.4. By Stem Cell Type

    16.13. India

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2021

            16.13.2.1. By Therapy Type

            16.13.2.2. By Indication

            16.13.2.3. By End User

            16.13.2.4. By Stem Cell Type

    16.14. Thailand

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2021

            16.14.2.1. By Therapy Type

            16.14.2.2. By Indication

            16.14.2.3. By End User

            16.14.2.4. By Stem Cell Type

    16.15. Indonesia

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2021

            16.15.2.1. By Therapy Type

            16.15.2.2. By Indication

            16.15.2.3. By End User

            16.15.2.4. By Stem Cell Type

    16.16. Malaysia

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2021

            16.16.2.1. By Therapy Type

            16.16.2.2. By Indication

            16.16.2.3. By End User

            16.16.2.4. By Stem Cell Type

    16.17. Singapore

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2021

            16.17.2.1. By Therapy Type

            16.17.2.2. By Indication

            16.17.2.3. By End User

            16.17.2.4. By Stem Cell Type

    16.18. Australia

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2021

            16.18.2.1. By Therapy Type

            16.18.2.2. By Indication

            16.18.2.3. By End User

            16.18.2.4. By Stem Cell Type

    16.19. New Zealand

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2021

            16.19.2.1. By Therapy Type

            16.19.2.2. By Indication

            16.19.2.3. By End User

            16.19.2.4. By Stem Cell Type

    16.20. GCC Countries

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2021

            16.20.2.1. By Therapy Type

            16.20.2.2. By Indication

            16.20.2.3. By End User

            16.20.2.4. By Stem Cell Type

    16.21. South Africa

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2021

            16.21.2.1. By Therapy Type

            16.21.2.2. By Indication

            16.21.2.3. By End User

            16.21.2.4. By Stem Cell Type

    16.22. Israel

        16.22.1. Pricing Analysis

        16.22.2. Market Share Analysis, 2021

            16.22.2.1. By Therapy Type

            16.22.2.2. By Indication

            16.22.2.3. By End User

            16.22.2.4. By Stem Cell Type

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Therapy Type

        17.3.3. By Indication

        17.3.4. By End User

        17.3.5. By Stem Cell Type

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. Vericel Corporation

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. Cyagen Biosciences, Inc.

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. Stemcell Technologies Inc.

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. Celegene Corporation

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. Cellular Dynamics International

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. Cytori Therapeutics, Inc.

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. Fibrocell Science, Inc.

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. Mesoblast Ltd

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. Regeneus Ltd

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. EMD Millipore Corporation

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

        18.1.11. ReNeuron Group plc

            18.1.11.1. Overview

            18.1.11.2. Product Portfolio

            18.1.11.3. Profitability by Market Segments

            18.1.11.4. Sales Footprint

            18.1.11.5. Strategy Overview

                18.1.11.5.1. Marketing Strategy

        18.1.12. International Stem Cell Corporation

            18.1.12.1. Overview

            18.1.12.2. Product Portfolio

            18.1.12.3. Profitability by Market Segments

            18.1.12.4. Sales Footprint

            18.1.12.5. Strategy Overview

                18.1.12.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療)の最新刊レポート


よくあるご質問


Future Market Insights社はどのような調査会社ですか?


Future Market Insights(FMI)は世界の広範な地域および産業を対象にした調査レポートを出版しています。  弊社ウェブサイトに掲載のないタイトルも全てお取り扱い可能ですので... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/12/18 10:27

154.74 円

162.88 円

199.42 円

ページTOPに戻る